Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development. So we are in fairly close agreement. That Continue reading QIDP Drug Update – Part 2: Categories of Interest
It is time for a new look at the field of QIDP drugs. Today we are providing an updated searchable database which now has 57 entries. (Status: 10/18/16) Despite best efforts to provide accurate information, errors may have crept in. Please let us Continue reading QIDP Drug Update – Part 1: An Updated Who Is Who
For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down: 31 compounds with QIDP designation 29 antibacterials, 2 antifungals 22 systemically active, Continue reading QIDP Drugs: Here They Are, All of Them
Preclinical and early clinical development is expensive enough already for VC companies but it gets really expensive in Phase 3. Hence, not surprisingly, few small companies tackle Phase 3 programs on their own. Unless an ‘angel investor’ with deep pockets Continue reading The Difficult Transition Into Phase 3
The pleuromutilins are a relatively ‘old’ class of antibiotics that have seen much use in veterinary but not in human medicine. According to EMA, Tiamulin is an “essential antibiotic” for the control of dysentery in pigs which is caused by Continue reading BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3